Literature DB >> 1827556

Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.

W M van Weerden1, A van Kreuningen, E P Moerings, F H de Jong, G J van Steenbrugge, F H Schröder.   

Abstract

The transplantable androgen-dependent human prostate tumor models PC-82 and PC-EW were used to study whether low levels of testosterone and androgens of adrenal origin were capable of stimulating the growth of prostatic carcinoma cells in these tumor models. At all circulating plasma testosterone levels applied in this study, much lower levels of dihydrotestosterone were found in PC-EW tumor tissue than in PC-82 tumor tissue. Nevertheless, both prostate tumor models had a similar threshold level of dihydrotestosterone for growth stimulation, i.e. 3-4 pmol/g tissue. This critical androgen level for tumor growth amounted to 2-3 times the tissue level found in castrated animals. At this threshold level approximately 2% of the cells showed proliferative activity, as assessed by bromodeoxyuridine incorporation into DNA. The adrenal androgen dehydroepiandrosterone did not stimulate PC-82 tumor growth, whereas androstenedione did induce a moderate increase in tumor volume. It is concluded that the adrenal androgen androstenedione exerts a stimulating effect on prostatic cancer cells when its conversion results in intra-tissue testosterone and dihydrotestosterone levels exceeding the threshold level for tumor growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827556     DOI: 10.1007/bf00294011

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  27 in total

1.  Subdivision of S-phase by analysis of nuclear 5-bromodeoxyuridine staining patterns.

Authors:  J H van Dierendonck; R Keyzer; C J van de Velde; C J Cornelisse
Journal:  Cytometry       Date:  1989-03

2.  Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

Authors:  M E Harper; A Pike; W B Peeling; K Griffiths
Journal:  J Endocrinol       Date:  1974-01       Impact factor: 4.286

3.  Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82).

Authors:  G J van Steenbrugge; M Groen; J C Romijn; F H Schröder
Journal:  J Urol       Date:  1984-04       Impact factor: 7.450

4.  Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.

Authors:  W J Ellis; J T Isaacs
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701

5.  Studies with anti-bromodeoxyuridine antibodies: II. Simultaneous immunocytochemical detection of antigen expression and DNA synthesis by in vivo labeling of mouse intestinal mucosa.

Authors:  B Schutte; M M Reynders; F T Bosman; G H Blijham
Journal:  J Histochem Cytochem       Date:  1987-03       Impact factor: 2.479

6.  Orchidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids.

Authors:  R Stege; A Eriksson; P Henriksson; K Carlström
Journal:  Int J Androl       Date:  1987-08

7.  Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.

Authors:  J T Isaacs; D S Coffey
Journal:  Cancer Res       Date:  1981-12       Impact factor: 12.701

8.  Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate.

Authors:  C Labrie; J Simard; H F Zhao; A Belanger; G Pelletier; F Labrie
Journal:  Endocrinology       Date:  1989-06       Impact factor: 4.736

9.  Assessment of the critical level of androgen for growth response of transplantable human prostatic carcinoma (PC-82) in nude mice.

Authors:  W M van Weerden; G J van Steenbrugge; A van Kreuningen; E P Moerings; F H de Jong; F H Schröder
Journal:  J Urol       Date:  1991-03       Impact factor: 7.450

10.  Comparison of dihydrotestosterone levels in prostatic cancer metastases and primary prostate cancer.

Authors:  J Geller; C D Candari
Journal:  Prostate       Date:  1989       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.